Different Effects of FK317 on Multidrug‐resistant Tumor in vivo and in vitro

FK317, a novel substituted dihydrobenzoxazine, was examined for antitumor effects on multidrug‐resistant (MDR) tumor cells in vitro and in vivo. In nude mice, FK317 markedly inhibited the growth of s.c. implanted KB‐V1 vinblastine (VLB)‐resistant human epidermal carcinoma KB cells, as well as the parent cells (KB‐3‐1). However, KB‐V1 showed much greater resistance to FK317 than to VLB and adriamycin (ADM) in the in vitro study. This resistance was reversed by the addition of verapamil, whereby intracellular accumulation of FK317 in the KB‐V1 cells was also decreased. After incubation of FK317 in human and mouse blood, it was shown to be rapidly metabolized to a monodeacetylated form, and slowly metabolized further to a dideacetylated form. With the removal of the acetyl groups from FK317, resistance indexes in KB‐V1 and SBC‐3/ADM, ADM‐resistant human lung carcinoma, decreased. In addition, photolabeling of P‐glycoprotein with [3H]azidopine in KB‐V1 plasma membrane was completely inhibited by FK317, but not by the deacetylated metabolites. These results indicate that FK317 is metabolized to deacetylated forms, which do not bind to P‐glycoprotein and are incorporated into MDR cells, causing cytotoxic effects.

[1]  K. Miyamoto,et al.  Establishment by Adriamycin Exposure of Multidrug‐resistant Rat Ascites Hepatoma AH130 Cells Showing Low DT‐diaphorase Activity and High Cross Resistance to Mitomycins , 1997, Japanese journal of cancer research : Gann.

[2]  K. Kiura,et al.  Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance. , 1993, Acta medica Okayama.

[3]  I. Pastan,et al.  Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Ries,et al.  Genetic aspects of multidrug resistance , 1992, Medical oncology and tumor pharmacotherapy.

[5]  T. Tsuruo,et al.  Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. , 1991, Cancer research.

[6]  T. Nakamura,et al.  Interstrand DNA-DNA and DNA-protein cross-links by a new antitumor antibiotic, FK973, in L1210 cells. , 1988, Cancer research.

[7]  H L Pearce,et al.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.

[8]  T. Nakamura,et al.  Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice. , 1988, Cancer research.

[9]  T. Tsuruo,et al.  Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. , 1988, The Journal of biological chemistry.

[10]  R. Lipton,et al.  Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.

[11]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[12]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[13]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[14]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[15]  I. Pastan,et al.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. , 1986, The Journal of biological chemistry.

[16]  I. Pastan,et al.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[18]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[19]  R. Nagel,et al.  Esterase activity of hemoglobin. Differences between HB A and HB S. , 1981, The Journal of biological chemistry.

[20]  O. Lockridge,et al.  Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. , 1980, The Journal of pharmacology and experimental therapeutics.

[21]  R. Johnson,et al.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. , 1979, Cancer research.

[22]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[23]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[24]  I. Kawamura,et al.  FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome , 1998, Cancer Chemotherapy and Pharmacology.

[25]  A. Safa.  Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. , 1993, Cancer investigation.

[26]  水野 公雄.  Mitomycin C cross-resistance induced by Adriamycin in human ovarian cancer cells in vitro , 1992 .